Overview

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer

Status:
RECRUITING

Trial end date:
2031-12-01

Target enrollment:

Participant gender:

Summary

The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.

Phase:

PHASE3

Details

Lead Sponsor:

Gustave Roussy, Cancer Campus, Grand Paris

Collaborator:

AstraZeneca

Treatments:

BID protein, human
olaparib